1
|
Hoang D, Broer N, Roman SA, Yao X, Abitbol N, Li F, Sosa JA, Sue GR, DeWan AT, Wong ML, Licinio J, Simpson C, Li AY, Pizzoferrato N, Narayan D. Leptin signaling and hyperparathyroidism: clinical and genetic associations. J Am Coll Surg 2013; 218:1239-1250.e4. [PMID: 24468228 DOI: 10.1016/j.jamcollsurg.2013.11.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Revised: 11/09/2013] [Accepted: 11/18/2013] [Indexed: 02/02/2023]
Abstract
BACKGROUND The role of leptin in mediating calcium-related metabolic processes is not well understood. STUDY DESIGN We enrolled patients with hyperparathyroidism undergoing parathyroidectomy in a prospective study to assess postoperative changes to serum leptin and parathyroid hormone levels and to determine the presence of LEPR (leptin receptor) polymorphisms. Patients undergoing hemithyroidectomy under identical surgical conditions were enrolled as controls. Wilcoxon signed-rank test was used to analyze changes in leptin. Pearson correlations and Bland-Altman methods were used to examine the between-subject and within-subject correlations in changes in leptin and parathyroid hormone levels. Five single-nucleotide polymorphisms in the LEPR gene were genotyped, and linear regression analysis was performed for each polymorphism. RESULTS Among the 71 patients included in the clinical study, after-surgery leptin levels decreased significantly in the parathyroid adenoma (p < 0.001) and parathyroid hyperplasia subgroups (p = 0.002) and increased in the control group (p = 0.007). On multivariate analysis, parathyroid disease subtype, baseline leptin levels, age, body mass index, and calcium at diagnosis was associated with changes in leptin. Among the 132 patients included in the genotyping analysis, under a recessive model of inheritance, single-nucleotide polymorphism rs1137101 had a significant association with the largest parathyroid gland and total mass of parathyroid tissue removed (p = 0.045 and p = 0.040, respectively). When analyzing obese patients only, rs1137100 and rs1137101 were significantly associated with total parathyroid size (p = 0.0343 and p = 0.0259, respectively). CONCLUSIONS Our results suggest a role for the parathyroid gland in regulating leptin production. Genetic contributions from the leptin pathway might predispose to hyperparathyroidism.
Collapse
Affiliation(s)
- Don Hoang
- Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT
| | - Niclas Broer
- Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT
| | - Sanziana A Roman
- Section of Endocrine Surgery, Department of Surgery, Duke University School of Medicine, Durham, NC
| | - Xiaopan Yao
- Yale Center of Analytical Science, Yale University School of Public Health, New Haven, CT
| | - Nathalie Abitbol
- Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT
| | - Fangyong Li
- Yale Center of Analytical Science, Yale University School of Public Health, New Haven, CT
| | - Julie A Sosa
- Section of Endocrine Surgery, Department of Surgery, Duke University School of Medicine, Durham, NC
| | - Gloria R Sue
- Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT
| | - Andrew T DeWan
- Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, CT
| | - Ma-Li Wong
- Mind and Brain Theme, South Australian Health and Medical Research Institute and Department of Psychiatry, School of Medicine, Flinders University, Adelaide, South Australia
| | - Julio Licinio
- Mind and Brain Theme, South Australian Health and Medical Research Institute and Department of Psychiatry, School of Medicine, Flinders University, Adelaide, South Australia
| | - Christine Simpson
- Department of Internal Medicine, Yale University School of Medicine, New Haven, CT
| | - Alexander Y Li
- Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT
| | - Nicole Pizzoferrato
- Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, CT
| | - Deepak Narayan
- Section of Plastic and Reconstructive Surgery, Department of Surgery, Yale University School of Medicine, New Haven, CT.
| |
Collapse
|
2
|
Ramsay TG, Rosebrough RW. Regulation of uncoupling proteins 2 and 3 in porcine adipose tissue. Domest Anim Endocrinol 2005; 28:351-66. [PMID: 15826771 DOI: 10.1016/j.domaniend.2004.12.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/18/2004] [Accepted: 12/22/2004] [Indexed: 11/22/2022]
Abstract
This study was performed to determine whether or not uncoupling protein 2 (UCP2) and UCP3 expression in porcine subcutaneous adipose tissue are hormonally regulated in vitro and whether their expression is correlated with changes in metabolic activity. Tissue slices (approximately 100 mg) were placed in 12-well plates containing 1 mL of DMEM/F12 with 25 mM Hepes, 0.5% BSA, pH 7.4. Triplicate slices were incubated with basal medium or hormone supplemented media at 37 degrees C with 95% air/5% CO2. Parallel cultures were maintained for either 2 or 24 h to evaluate metabolic viability of the tissue. Slices were transferred to test tubes containing 1 mL of DMEM/F12 with 25 mM Hepes, 3% BSA, 5.5 mM glucose, 1 microCi 14C-U-glucose/mL and incubated for an additional 2 h at 37 degrees C. Glucose metabolism in 2-h incubations did not differ from 24-h (chronic) incubations, indicating viability was maintained (P>0.05). Expression of UCP2 and UCP3 was assessed in slices following 24h of incubation with various combinations of hormones by semi-quantitative RT-PCR. Expression of UCP2 was induced by leptin (100 ng/mL; P<0.05). Growth hormone (100 ng/mL) inhibited UCP2 expression (P<0.05). Expression of UCP3 was inhibited by growth hormone (100 ng/mL; P<0.05), tri-iodothyronine (10 nM; P<0.05) or leptin (100 ng/mL; P<0.05). Changes in UCP expression could not be associated with overall changes in glucose metabolism by adipose tissue slices in chronic culture.
Collapse
Affiliation(s)
- T G Ramsay
- Growth Biology Laboratory, USDA-ARS, BARC-East, Bldg. 200, Rm. 207, Beltsville, MD 20705, USA.
| | | |
Collapse
|
3
|
Abstract
The discovery of leptin was a major breakthrough in our understanding of the role of adipose tissue as a storage and secretory organ. Leptin was initially thought to act mainly to prevent obesity; however, studies have demonstrated profound effects of leptin in the response to fasting, regulation of neuroendocrine and immune systems, hematopoiesis, bone and brain development. This review will focus on the signaling pathways which mediate these diverse effects of leptin in the brain and other physiologic systems.
Collapse
Affiliation(s)
- Rexford S Ahima
- Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, University of Pennsylvania School of Medicine, 415 Curie Boulevard, 764 Clinical Research Building, Philadelphia, PA 19104, USA.
| | | |
Collapse
|
4
|
Holmes AG, Watt MJ, Febbraio MA. Suppressing lipolysis increases interleukin-6 at rest and during prolonged moderate-intensity exercise in humans. J Appl Physiol (1985) 2004; 97:689-96. [PMID: 15075299 DOI: 10.1152/japplphysiol.00195.2004] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
IL-6 induces lipolysis when administered to humans. Consequently, it has been hypothesized that IL-6 is released from skeletal muscle during exercise to act in a “hormonelike” manner and increase lipolysis from adipose tissue to supply the muscle with substrate. In the present study, we hypothesized that suppressing lipolysis, and subsequent free fatty acid (FFA) availability, would result in a compensatory elevation in IL-6 at rest and during exercise. First, we had five healthy men ingest nicotinic acid (NA) at 30-min intervals for 120 min at rest [10 mg/kg body mass (initial dose), 5 mg/kg body mass (subsequent doses)]. Plasma was collected and analyzed for FFA and IL-6. After 120 min, plasma FFA concentration was attenuated (0 min: 0.26 ± 0.05 mmol/l; 120 min: 0.09 ± 0.02 mmol/l; P < 0.01), whereas plasma IL-6 was concomitantly increased approximately eightfold (0 min: 0.75 ± 0.18 pg/ml; 120 min: 6.05 ± 0.89 pg/ml; P < 0.001). To assess the effect of lipolytic suppression on the exercise-induced IL-6 response, seven active, but not specifically trained, men performed two experimental exercise trials with (NA) or without [control (Con)] NA ingestion 60 min before (10 mg/kg body mass) and throughout (5 mg/kg body mass every 30 min) exercise. Blood samples were obtained before ingestion, 60 min after ingestion, and throughout 180 min of cycling exercise at 62 ± 5% of maximal oxygen consumption. IL-6 gene expression, in muscle and adipose tissue sampled at 0, 90, and 180 min, was determined by using semiquantitative real-time PCR. IL-6 mRNA increased in Con (rest vs. 180 min; P < 0.01) ∼13-fold in muscle and ∼42-fold in fat with exercise. NA increased (rest vs. 180 min; P < 0.01) IL-6 mRNA 34-fold in muscle, but the treatment effect was not statistically significant (Con vs. NA, P = 0.1), and 235-fold in fat (Con vs. NA, P < 0.01). Consistent with the study at rest, NA completely suppressed plasma FFA (180 min: Con, 1.42 ± 0.07 mmol/l; NA, 0.10 ± 0.01 mmol/l; P < 0.001) and increased plasma IL-6 (180 min: Con, 9.81 ± 0.98 pg/ml; NA, 19.23 ± 2.50 pg/ml; P < 0.05) during exercise. In conclusion, these data demonstrate that circulating IL-6 is markedly elevated at rest and during prolonged moderate-intensity exercise when lipolysis is suppressed.
Collapse
Affiliation(s)
- Anna G Holmes
- Skeletal Muscle Research Laboratory, School of Medical Sciences, RMIT University, P.O. Box 71, Bundoora 3083, Victoria, Australia
| | | | | |
Collapse
|
5
|
Scacchi M, Pincelli AI, Cavagnini F. Nutritional status in the neuroendocrine control of growth hormone secretion: the model of anorexia nervosa. Front Neuroendocrinol 2003; 24:200-24. [PMID: 14596812 DOI: 10.1016/s0091-3022(03)00014-1] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Growth hormone (GH) plays a key role not only in the promotion of linear growth but also in the regulation of intermediary metabolism, body composition, and energy expenditure. On the whole, the hormone appears to direct fuel metabolism towards the preferential oxidation of lipids instead of glucose and proteins, and to convey the energy derived from metabolic processes towards the synthesis of proteins. On the other hand, body energy stores and circulating energetic substrates take an important part in the regulation of somatotropin release. Finally, central and peripheral peptides participating in the control of food intake and energy expenditure (neuropeptide Y, leptin, and ghrelin) are also involved in the regulation of GH secretion. Altogether, nutritional status has to be regarded as a major determinant in the regulation of the somatotropin-somatomedin axis in animals and humans. In these latter, overweight is associated with marked impairment of spontaneous and stimulated GH release, while acute dietary restriction and chronic undernutrition induce an amplification of spontaneous secretion together with a clear-cut decrease in insulin-like growth factor I (IGF-I) plasma levels. Thus, over- and undernutrition represent two conditions connoted by GH hypersensitivity and GH resistance, respectively. Anorexia nervosa (AN) is a psychiatric disorder characterized by peculiar changes of the GH-IGF-I axis. In these patients, low circulating IGF-I levels are associated with enhanced GH production rate, highly disordered mode of somatotropin release, and variability of GH responsiveness to different pharmacological challenges. These abnormalities are likely due not only to the lack of negative IGF-I feedback, but also to a primary hypothalamic alteration with increased frequency of growth hormone releasing hormone discharges and decreased somatostatinergic tone. Given the reversal of the above alterations following weight recovery, these abnormalities can be seen as secondary, and possibly adaptive, to nutritional deprivation. The model of AN may provide important insights into the pathophysiology of GH secretion, in particular as regards the mechanisms whereby nutritional status effects its regulation.
Collapse
Affiliation(s)
- Massimo Scacchi
- Chair of Endocrinology, University of Milan, Ospedale San Luca IRCCS, Istituto Auxologico Italiano, Milan, Italy
| | | | | |
Collapse
|
6
|
Randeva HS, Murray RD, Lewandowski KC, O'Callaghan CJ, Horn R, O'Hare P, Brabant G, Hillhouse EW, Shalet SM. Differential effects of GH replacement on the components of the leptin system in GH-deficient individuals. J Clin Endocrinol Metab 2002; 87:798-804. [PMID: 11836324 DOI: 10.1210/jcem.87.2.8238] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
GH therapy is associated with a reduction in fat mass and an increase in lean mass in subjects with GH deficiency (GHD). Leptin, like GH, plays an important role in the regulation of body composition. GH treatment has been shown to reduce serum leptin; however, the physiological interactions between the leptin system (free leptin, bound leptin, and soluble leptin receptor) and the GH/IGF-I system largely remain unknown. Twenty-five patients with childhood (n = 10) and adult-onset (n = 15) GHD were studied. GH status had previously been determined using an insulin tolerance test and/or an arginine stimulation test. The following parameters were recorded at baseline (V1) and then after 3 months (V2) and 6 months (V3) on GH treatment: fat mass, body mass index (BMI), and waist/hip ratio (WHR); blood samples were taken after an overnight fast for free leptin, bound leptin, soluble leptin receptor, insulin, and IGF-I. At V2 and V3, respectively, a fall in free leptin (P < 0.001 for each), and at V3 a fall in in percent fat mass (P < 0.001) were observed. There were no significant changes in BMI or WHR. Simultaneously, there was a rise in insulin (P = 0.068 and P < 0.001), IGF-I (P < 0.001 and P < 0.001), bound leptin (P = 0.005 and P < 0.001), and soluble leptin receptor (P = 0.61 and P < 0.001). A positive relationship was noted between free leptin and BMI (P < 0.001) and between free leptin and fat mass (P < 0.001), and a negative relationship was found between free leptin and IGF-I (P < 0.001) and, within patient, between free leptin and insulin (P < 0.001). There was no significant correlation between free leptin and WHR. Bound leptin had a positive association with IGF-I (P < 0.001) and insulin (P = 0.002) and a negative relationship with percent fat mass (P = 0.023). Soluble leptin receptor was also positively related to IGF-I (P < 0.001). In conclusion, our data suggest that the reduction in serum leptin with GH treatment, as noted by others, is mediated through a fall in free leptin. The fall in free leptin and in part the rise in bound leptin are most likely through a reduction in percent fat mass. However, the observed changes in free leptin and bound leptin and, more importantly, the rise in soluble leptin receptor, are not explained entirely by modifications in body composition and may be a direct result of GH/IGF-I.
Collapse
Affiliation(s)
- Harpal S Randeva
- Sir Quinton Hazel Molecular Medicine Research Center, Biological Sciences, University of Warwick, Coventry, United Kingdom CV4 7AL
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Abstract
The effect of an acute bolus of GH on serum leptin in normal individuals and the factors affecting this response have not previously been studied. Seventeen healthy volunteers with normal body mass index, with ages ranging from 20.5-78.2 yr were studied. Each subject received three single doses of GH in random order at least 4 wk apart. Bioimpedence analysis was performed to provide estimates of fat and lean masses. Serum samples for leptin, insulin, and IGF-I were taken 0, 18, 24, 48, 72, and 120 h after each dose of GH. Leptin levels changed significantly after the 0.67- and 7-mg doses of GH, but not after the 0.27-mg dose. Compared with baseline, there was a significant elevation (P < 0.001) in serum leptin levels at 24 h, followed by a significant decrease (P < 0.01) at 72 h. Baseline and peak leptin levels were significantly determined by gender, fat mass, and log(10) insulin. Nadir leptin levels were significantly determined by gender and fat mass. In contrast, the increment in leptin levels was significantly determined by age, although this only accounted for 24% of the variability in the increment in leptin levels. We have demonstrated that administration of a single bolus dose of GH significantly increases serum leptin levels, followed by a significant nadir. This occurs not only after a supraphysiological dose of GH, but also after 0.67 mg, a dose within the physiological replacement range. The increment in leptin increases with advancing age, suggesting that at the level of the adipocyte, aging increases responsiveness to GH. However, this only partially explains the changes seen, and it is likely that another factor(s) is involved in the acute impact of GH on circulating leptin levels. The presence of a significant nadir after the peak in leptin levels supports the existence of a negative feedback loop, linking circulating leptin to its own biosynthesis in adipose tissue, mediated by peripheral leptin receptors. These data provide unequivocal evidence that GH can affect serum leptin levels in the absence of a change in body composition.
Collapse
Affiliation(s)
- C A Lissett
- Department of Endocrinology, Christie Hospital, Manchester, United Kingdom M20 4BX
| | | | | |
Collapse
|
8
|
Fain JN, Cowan GS, Buffington C, Andersen RN, Pouncey L, Bahouth SW. Regulation of leptin release by troglitazone in human adipose tissue. Metabolism 2000; 49:1485-90. [PMID: 11092516 DOI: 10.1053/meta.2000.17675] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
In pieces of human subcutaneous adipose tissue incubated in primary culture for 48 hours, the release of leptin was stimulated by 50% in the presence of 3.3 micromol/L troglitazone. Insulin (0.1 nmol/L) and dexamethasone (200 nmol/L) stimulated leptin release by 30% and 300%, respectively. Troglitazone in combination with either insulin or dexamethasone had no effect on leptin release. Instead, troglitazone inhibited leptin release in the presence of both dexamethasone and insulin. The stimulatory effect of troglitazone on leptin release was also mimicked by 1 micromol/L 15-deoxy-delta(12-14)prostaglandin J2 (dPGJ2). However, if the concentration of dPGJ2 was increased to 10 micromol/L in the presence of dexamethasone, there was a decrease in leptin release, as well as of lactate formation and lipolysis. These data indicate that both stimulatory and inhibitory effects of troglitazone and dPGJ2 can be seen on leptin release by human adipose tissue.
Collapse
Affiliation(s)
- J N Fain
- Department of Biochemistry, College of Medicine, University of Tennessee, Memphis 38163, USA
| | | | | | | | | | | |
Collapse
|
9
|
Fain JN, Leffler CW, Bahouth SW, Rice AM, Rivkees SA. Regulation of leptin release and lipolysis by PGE2 in rat adipose tissue. Prostaglandins Other Lipid Mediat 2000; 62:343-50. [PMID: 11060898 DOI: 10.1016/s0090-6980(00)00088-5] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The role of eicosanoids formed by adipose tissue from rats was examined in the presence of the specific cyclooxygenase-2 inhibitor NS-398. This agent totally blocked the release of prostaglandin E2 (PGE2) by rat adipose tissue over a 24-h incubation in primary culture. The final concentration of PGE2 after 24 h was 12 nM, and half-maximal inhibition of PGE2 formation required 35 nM NS-398. While inhibition of PGE2 formation by NS-398 had no effect on basal leptin release or lipolysis, it enhanced the lipolytic action of 10 nM isoproterenol by 36%. The in vivo administration of PGE2 doubled serum leptin. PGE2 also directly stimulated leptin release by rat adipose tissue incubated in the presence of 25 nM dexamethasone, which inhibited endogenous PGE2 formation by 94%. The inhibition of lipolysis as well as the stimulation of leptin release by PGE2 were mimicked by N6-cyclopentyladenosine (CPA). These data indicate that exogenous PGE2 can stimulate leptin release by adipose tissue when the basal formation of PGE2 is blocked by dexamethasone. However, while the endogenous formation of PGE2 does not appear to regulate basal lipolysis or leptin release, it may play a role in the activation of lipolysis by catecholamines.
Collapse
Affiliation(s)
- J N Fain
- Department of Biochemistry, College of Medicine, University of Tennessee, Memphis 38163, USA.
| | | | | | | | | |
Collapse
|
10
|
Fain JN, Leffler CW, Bahouth SW. Eicosanoids as endogenous regulators of leptin release and lipolysis by mouse adipose tissue in primary culture. J Lipid Res 2000. [DOI: 10.1016/s0022-2275(20)32003-4] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
|
11
|
Fain JN, Bahouth SW. Regulation of leptin release by mammalian adipose tissue. Biochem Biophys Res Commun 2000; 274:571-5. [PMID: 10924319 DOI: 10.1006/bbrc.2000.3168] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- J N Fain
- Department of Biochemistry, University of Tennessee, Memphis, Memphis, Tennessee, 38163, USA
| | | |
Collapse
|
12
|
Abstract
The discovery of leptin has enhanced understanding of the interrelationship between adipose energy stores and neuronal circuits in the brain involved in energy balance and regulation of the neuroendocrine axis. Leptin levels are dependent on the status of fat stores as well as changes in energy balance as a result of fasting and overfeeding. Although leptin was initially thought to serve mainly as an anti-satiety hormone, recent studies have shown that it mediates the adaptation to fasting. Furthermore, leptin has been implicated in the regulation of the reproductive, thyroid, growth hormone, and adrenal axes, independent of its role in energy balance. Although it is widely known that leptin acts on hypothalamic neuronal targets to regulate energy balance and neuroendocrine function, the specific neuronal populations mediating leptin action on feeding behavior and autonomic and neuroendocrine function are not well understood. In this review, we have discussed how leptin engages arcuate hypothalamic neurons expressing putative orexigenic peptides, e.g., neuropeptide Y and agouti-regulated peptide, and anorexigenic peptides, e.g., pro-opiomelanocortin (precursor of alpha-melanocyte-stimulating hormone) and cocaine- and amphetamine-regulated transcript. We show that leptin's effects on energy balance and the neuroendocrine axis are mediated by projections to other hypothalamic nuclei, e.g., paraventricular, lateral, and perifornical areas, as well as other sites in the brainstem, spinal cord, and cortical and subcortical regions.
Collapse
Affiliation(s)
- R S Ahima
- Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, 19104, USA.
| | | | | | | |
Collapse
|
13
|
Fain JN, Cowan GS, Buffington C, Li J, Pouncey L, Bahouth SW. Synergism between insulin and low concentrations of isoproterenol in the stimulation of leptin release by cultured human adipose tissue. Metabolism 2000; 49:804-9. [PMID: 10877211 DOI: 10.1053/meta.2000.6244] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The release of leptin by pieces of human adipose tissue incubated in primary culture for 24 or 48 hours in the presence of dexamethasone was reduced by isoproterenol. An inhibition of leptin release was observed at 24 hours in the presence of isoproterenol and was mediated by beta1-adrenergic receptors, since it was blocked by the specific beta1-adrenoceptor antagonist CGP-20712A. The inhibitory effect of 33 nmol/L isoproterenol on leptin release was reversed in the presence of 0.1 nmol/L insulin to a 2-fold stimulation of leptin release. These data suggest that the primary mechanism by which insulin stimulates leptin release is to blunt the inhibitory effects of beta1-adrenergic receptor agonists, and low concentrations of catecholamines actually enhance the stimulation of leptin release by insulin.
Collapse
Affiliation(s)
- J N Fain
- Department of Biochemistry, College of Medicine, University of Tennessee, Memphis, USA
| | | | | | | | | | | |
Collapse
|